Sitagliptin and the risk of hospitalization for heart failure: a population-based study - PubMed (original) (raw)
. 2014 Nov 15;177(1):86-90.
doi: 10.1016/j.ijcard.2014.09.038. Epub 2014 Sep 28.
Affiliations
- PMID: 25499347
- DOI: 10.1016/j.ijcard.2014.09.038
Sitagliptin and the risk of hospitalization for heart failure: a population-based study
Kang-Ling Wang et al. Int J Cardiol. 2014.
Abstract
Background: Saxagliptin was associated with an increased risk of hospitalization for heart failure (HHF) in diabetic patients with high cardiovascular risk. This study assessed the risk of HHF during an exposure to sitagliptin in general diabetic patients.
Methods: In Taiwan National Health Insurance research database, a study of the beneficiaries aged ≥ 45 years with diabetes treated with or without sitagliptin between March 2009 and July 2011 was conducted. Patients treated with sitagliptin were matched to patients never exposed to a dipeptidyl peptidase-4 (DPP-4) inhibitor by the propensity score methodology. The outcome measures were the first and the total number of HHF, and mortality for heart failure or all causes.
Results: A total of 8288 matched pairs of patients were analyzed. During a median of 1.5 years, the first event of HHF occurred in 339 patients with sitagliptin and 275 patients never exposed to a DPP-4 inhibitor (hazard ratio: 1.21, 95% confidence interval: 1.04-1.42, P = 0.017); all-cause mortality was similar (hazard ratio: 0.87, 95% confidence interval: 0.74-1.03, P = 0.109). The risk for HHF was proportional to exposure (hazard ratio: 1.09, 95% confidence interval: 1.06-1.11, P < 0.001 for every 10% increase in adherence to sitagliptin). Overall, there were 935 events of HHF, in which the association between the number of HHF and the adherence to sitagliptin was linear. The greatest total number of HHF occurred in the patients with the highest adherence.
Conclusions: The use of sitagliptin was associated with a higher risk of HHF but no excessive risk for mortality was observed.
Keywords: Heart failure; Outcome research; Sitagliptin.
Copyright © 2014 Elsevier Ireland Ltd. All rights reserved.
Similar articles
- Association Between Sitagliptin Use and Heart Failure Hospitalization and Related Outcomes in Type 2 Diabetes Mellitus: Secondary Analysis of a Randomized Clinical Trial.
McGuire DK, Van de Werf F, Armstrong PW, Standl E, Koglin J, Green JB, Bethel MA, Cornel JH, Lopes RD, Halvorsen S, Ambrosio G, Buse JB, Josse RG, Lachin JM, Pencina MJ, Garg J, Lokhnygina Y, Holman RR, Peterson ED; Trial Evaluating Cardiovascular Outcomes With Sitagliptin (TECOS) Study Group. McGuire DK, et al. JAMA Cardiol. 2016 May 1;1(2):126-35. doi: 10.1001/jamacardio.2016.0103. JAMA Cardiol. 2016. PMID: 27437883 Clinical Trial. - No increased risk of hospitalization for heart failure for patients treated with dipeptidyl peptidase-4 inhibitors in Taiwan.
Chang CH, Chang YC, Lin JW, Caffrey JL, Wu LC, Lai MS, Chuang LM. Chang CH, et al. Int J Cardiol. 2016 Oct 1;220:14-20. doi: 10.1016/j.ijcard.2016.06.125. Epub 2016 Jun 24. Int J Cardiol. 2016. PMID: 27389437 - Empagliflozin and the Risk of Heart Failure Hospitalization in Routine Clinical Care.
Patorno E, Pawar A, Franklin JM, Najafzadeh M, Déruaz-Luyet A, Brodovicz KG, Sambevski S, Bessette LG, Santiago Ortiz AJ, Kulldorff M, Schneeweiss S. Patorno E, et al. Circulation. 2019 Jun 18;139(25):2822-2830. doi: 10.1161/CIRCULATIONAHA.118.039177. Epub 2019 Apr 8. Circulation. 2019. PMID: 30955357 Free PMC article. - Cardiovascular effects of dipeptidyl peptidase-4 inhibitors: from risk factors to clinical outcomes.
Scheen AJ. Scheen AJ. Postgrad Med. 2013 May;125(3):7-20. doi: 10.3810/pgm.2013.05.2659. Postgrad Med. 2013. PMID: 23748503 Review. - Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes: focus on sitagliptin.
Herman GA, Stein PP, Thornberry NA, Wagner JA. Herman GA, et al. Clin Pharmacol Ther. 2007 May;81(5):761-7. doi: 10.1038/sj.clpt.6100167. Epub 2007 Mar 28. Clin Pharmacol Ther. 2007. PMID: 17392725 Review.
Cited by
- Pattern, frequency and factors associated with inappropriate high dosing in chronic kidney disease patients at a tertiary care hospital in Pakistan.
Hayat M, Ahmad N, Khan SLA, Mohkumuddin S, Siddique W, Khan A, Atif M. Hayat M, et al. BMC Nephrol. 2023 May 1;24(1):118. doi: 10.1186/s12882-023-03167-5. BMC Nephrol. 2023. PMID: 37127612 Free PMC article. - Type 2 Diabetes Complicated With Heart Failure: Research on Therapeutic Mechanism and Potential Drug Development Based on Insulin Signaling Pathway.
Ye H, He Y, Zheng C, Wang F, Yang M, Lin J, Xu R, Zhang D. Ye H, et al. Front Pharmacol. 2022 Mar 3;13:816588. doi: 10.3389/fphar.2022.816588. eCollection 2022. Front Pharmacol. 2022. PMID: 35308248 Free PMC article. Review. - Long-Term Dipeptidyl Peptidase 4 Inhibition Worsens Hypertension and Renal and Cardiac Abnormalities in Obese Spontaneously Hypertensive Heart Failure Rats.
Jackson EK, Mi Z, Gillespie DG, Cheng D, Tofovic SP. Jackson EK, et al. J Am Heart Assoc. 2021 Mar 16;10(6):e020088. doi: 10.1161/JAHA.120.020088. Epub 2021 Mar 8. J Am Heart Assoc. 2021. PMID: 33682436 Free PMC article. - Risk of cardiovascular events associated with dipeptidyl peptidase-4 inhibitors in patients with diabetes with and without chronic kidney disease: A nationwide cohort study.
Huang TL, Hsiao FY, Chiang CK, Shen LJ, Huang CF. Huang TL, et al. PLoS One. 2019 May 21;14(5):e0215248. doi: 10.1371/journal.pone.0215248. eCollection 2019. PLoS One. 2019. PMID: 31112536 Free PMC article. - Heart Failure Hospitalization with DPP-4 Inhibitors: A Systematic Review and Meta-analysis of Randomized Controlled Trials.
Singh AK, Singh R. Singh AK, et al. Indian J Endocrinol Metab. 2019 Jan-Feb;23(1):128-133. doi: 10.4103/ijem.IJEM_613_18. Indian J Endocrinol Metab. 2019. PMID: 31016167 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous